Pasithea Therapeutics (KTTA) Leases (2021 - 2024)
Historic Leases for Pasithea Therapeutics (KTTA) over the last 4 years, with Q1 2024 value amounting to $32026.0.
- Pasithea Therapeutics' Leases fell 9998.26% to $32026.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $32026.0, marking a year-over-year decrease of 9998.26%. This contributed to the annual value of $79271.0 for FY2023, which is 8415.94% down from last year.
- According to the latest figures from Q1 2024, Pasithea Therapeutics' Leases is $32026.0, which was down 9998.26% from $79271.0 recorded in Q4 2023.
- Over the past 5 years, Pasithea Therapeutics' Leases peaked at $184.2 million during Q1 2023, and registered a low of $32026.0 during Q1 2024.
- For the 4-year period, Pasithea Therapeutics' Leases averaged around $23.2 million, with its median value being $419885.0 (2023).
- As far as peak fluctuations go, Pasithea Therapeutics' Leases soared by 231.32% in 2023, and later plummeted by 9998.26% in 2024.
- Over the past 4 years, Pasithea Therapeutics' Leases (Quarter) stood at $21.5 million in 2021, then crashed by 97.67% to $500428.0 in 2022, then crashed by 84.16% to $79271.0 in 2023, then plummeted by 59.6% to $32026.0 in 2024.
- Its Leases was $32026.0 in Q1 2024, compared to $79271.0 in Q4 2023 and $378453.0 in Q3 2023.